Journal article Open Access

Molecular targets for AIDS therapy

Mitsuya, H.; Yarchoan, R.; Broder, S.

The development of antiretroviral therapy against acquired immunodeficiency syndrome (AIDS) has been an intense research effort since the discovery of the causative agent, human immunodeficiency virus (HIV). A large array of drugs and biologic substances can inhibit HIV replication in vitro. Nucleoside analogs--particularly those belonging to the dideoxynucleoside family--can inhibit reverse transcriptase after anabolic phosphorylation. 3'-Azido-2',3'-dideoxythymidine (AZT) was the first such drug tested in individuals with AIDS, and considerable knowledge of structure-activity relations has emerged for this class of drugs. However, virtually every step in the replication of HIV could serve as a target for a new therapeutic intervention. In the future, non-nucleoside-type drugs will likely become more important in the experimental therapy of AIDS, and antiretroviral therapy will exert major effects against the morbidity and mortality caused by HIV.

Files (3.0 MB)
Name Size
article.pdf
md5:4a123f9167e4a7392bb885c577731002
3.0 MB Download
289
145
views
downloads
Views 289
Downloads 145
Data volume 442.0 MB
Unique views 283
Unique downloads 136

Share

Cite as